EGFR and non-small cell lung carcinoma: A third-generation TKI, osimertinib, was first approved by the U.S. Food and Drug Administration (FDA) in 2015, under an accelerated approval pathway for the treatment of patients with metastatic NSCLC harboring the EGFR T790M mutation, following progression on earlier generations of TKI [5,12].